After Deutsche Bank and UBS gave Thermo Fisher (NYSE: TMO) a Buy rating last month, the company received another Buy, this time from Barclays. Analyst Jack Meehan maintained a Buy rating on Thermo Fisher yesterday and set a price target of $310. The company’s shares closed yesterday at $266.83.
According to TipRanks.com, Meehan is a 4-star analyst with an average return of 6.9% and a 62.1% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, PRA Health Sciences, and IQVIA Holdings Inc.
Thermo Fisher has an analyst consensus of Strong Buy, with a price target consensus of $298.83.
See today’s analyst top recommended stocks >>
Thermo Fisher’s market cap is currently $115.2B and has a P/E ratio of 36.82. The company has a Price to Book ratio of 4.17.
Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
